Tag
A phase 3 trial demonstrates that the oral combination of giredestrant and everolimus significantly improves progression-free survival in patients with ER-positive, HER2-negative advanced breast cancer post-CDK4/6 inhibitor therapy, especia
Results from the UTOLA trial reveal that ESR1 mutations, a hallmark of AI resistance in breast cancer, are present in 22% of metastatic NSMP low-grade endometrial cancer patients before endocrine therapy, suggesting a need for molecular str
This systematic review and network meta-analysis of 20 randomized trials demonstrate that molecular profiling for ESR1 and PI3K-AKT-PTEN alterations is essential for optimizing endocrine-based strategies after CDK4/6 inhibitor progression,
This real-world study demonstrates that elacestrant provides a durable benefit for patients with ER+/HER2- ESR1-mutated metastatic breast cancer, maintaining efficacy across various treatment lines and in patients with visceral metastases o
Roche announces positive phase 3 results of giredestrant plus everolimus, significantly reducing disease progression risk in ER+ HER2- advanced breast cancer patients post CDK4/6 inhibitor exposure, with favorable safety and promising survi
Next-generation SERD camizestrant significantly prolongs progression-free survival over aromatase inhibitors or fulvestrant in ESR1-mutated, ER-positive, HER2-negative advanced breast cancer, with favorable safety and quality-of-life profil
